Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 4
1984 2
1985 2
1986 5
1987 5
1988 6
1989 3
1990 5
1991 7
1992 15
1993 10
1994 6
1995 3
1996 3
1997 4
1998 7
1999 8
2000 11
2001 16
2002 21
2003 13
2004 29
2005 30
2006 13
2007 21
2008 27
2009 23
2010 24
2011 23
2012 22
2013 15
2014 12
2015 8
2016 4
2017 2
2018 1
2021 1
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Results by year

Filters applied: . Clear all
Page 1
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial.
Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Sever PS, et al. Among authors: dahlof b. Lancet. 2003 Apr 5;361(9364):1149-58. doi: 10.1016/S0140-6736(03)12948-0. Lancet. 2003. PMID: 12686036 Clinical Trial.
Introduction.
Ritz E, Dahlöf B. Ritz E, et al. Among authors: dahlof b. J Am Soc Hypertens. 2008 Jul-Aug;2(4 Suppl):S1-2. doi: 10.1016/j.jash.2008.03.005. J Am Soc Hypertens. 2008. PMID: 20409931 No abstract available.
Non-peptide AT2-receptor agonists.
Steckelings UM, Larhed M, Hallberg A, Widdop RE, Jones ES, Wallinder C, Namsolleck P, Dahlöf B, Unger T. Steckelings UM, et al. Among authors: dahlof b. Curr Opin Pharmacol. 2011 Apr;11(2):187-92. doi: 10.1016/j.coph.2010.11.002. Epub 2010 Dec 15. Curr Opin Pharmacol. 2011. PMID: 21167778 Review.
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Dahlöf B, et al. Lancet. 2002 Mar 23;359(9311):995-1003. doi: 10.1016/S0140-6736(02)08089-3. Lancet. 2002. PMID: 11937178 Clinical Trial.
Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT Investigators. Dahlöf B, et al. Lancet. 2005 Sep 10-16;366(9489):895-906. doi: 10.1016/S0140-6736(05)67185-1. Lancet. 2005. PMID: 16154016 Clinical Trial.
A reply.
Willenheimer R, Dahlöf B, Rydberg E, Erhardt L. Willenheimer R, et al. Among authors: dahlof b. Eur Heart J. 2000 Feb 15;21(4):336-337. doi: 10.1053/euhj.1999.1980. Eur Heart J. 2000. PMID: 10653685 No abstract available.
385 results